title: miR-129 as a novel therapeutic target and biomarker in gastrointestinal cancer.
abstract: In the last decade, cancer research efforts in the field of noncoding microRNA (miRNA) have been growing exponentially. miRNA-based therapeutics have been tested in both preclinical and clinical settings, and miRNA-based cancer diagnostics and prognostics have moved into clinics to help better manage cancer treatment. A growing body of evidence in recent literature suggests miRNA-129 plays important roles in gastrointestinal cancer, including gastric, colorectal, hepatocellular carcinoma, and esophageal cancer. In this review, we focus on accumulating evidence demonstrating the key roles that miRNA-129 plays in tumorigenesis, disease progression, chemoresistance, proliferation, and cell cycle control. Understanding the emerging roles and mechanisms of miRNA-129 in cancer will help us realize the therapeutic and diagnostic/prognostic potential.
authors.affiliation: Department of Pathology, Stony Brook Medicine, Stony Brook University, Stony Brook, NY, USA.
authors.forename: Andrew
authors.initials: A
authors.lastname: Fesler
authors.affiliation: Department of Pathology, Stony Brook Medicine, Stony Brook University, Stony Brook, NY, USA.
authors.forename: Haiyan
authors.initials: H
authors.lastname: Zhai
authors.affiliation: Department of Pathology, Stony Brook Medicine, Stony Brook University, Stony Brook, NY, USA.
authors.forename: Jingfang
authors.initials: J
authors.lastname: Ju
keywords: 5-FU; biomarker; cancer; miR-129; therapeutics